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Abstract.    A class of tripeptidyl transition state inhibitors containing a P1 glutamine surrogate, 
a P2 leucine, and a P3 arylalanines, was found to potently inhibit Norwalk virus replication in 
enzyme and cell based assays.  An array of warheads, including aldehyde, -ketoamide, bisulfite 
adduct, and -hydroxyphosphonate transition state mimic, was also investigated.  Tripeptidyls 2 
and 6 possess antiviral activities against noroviruses, human rhinovirus, severe acute respiratory 
syndrome coronavirus, and coronavirus 229E, suggesting a broad range of antiviral activities. 
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Viruses that belong to the Picornaviridae, Caliciviridae, and Coronaviridae families encode a 
3C or 3C-like protease (3Cpro or 3CLpro, respectively), which cleaves the viral polyproteins 
into mature or intermediate proteins and is essential for viral replication.1-3 Viruses in the 
Picornaviridae family include enteroviruses (EV),4 coxsakieviruses (CV), human rhinoviruses 
(HRV),5 and poliovirus (PV); viruses in the Caliciviridae family include human noroviruses such 
as Norwalk virus (NV) and MD145,2 and murine norovirus (MNV); and viruses in the 
Coronaviridae family include severe acute respiratory syndrome coronavirus (SARS-CoV)6 and 
human coronavirus 229E.  These viruses can cause outbreaks of acute gastroenteritis (NV),7 
severe systemic disease with high mortality (SARS-CoV),8,9 or a severe form of hand, foot and 
mouth disease (HFMD)10 associated with fatal encephalitis, paralysis, and myocarditis (EV71).  
Despite great efforts made in the discovery of preventive and therapeutic measures for these 
viruses,11 no antiviral drug or vaccine (except for poliovirus) is currently available. 
Viral 3Cpro and 3CLpro are cysteine proteases and share a typical chymotrypsin-like folding, a 
nucleophilic cysteine residue in the active site, and a preference for a glutamine or glutamic acid 
residue in the primary binding residue (P1 site) of the substrate proteins.12 The 3Cpro or 3CLpro 
of these viruses are appealing targets for the discovery of antiviral therapeutics, and the 
conservation of the proteases may provide an excellent platform for broad-spectrum antivirals for 
those important viruses.12 We report herein our design, synthesis, and bio-evaluation of a class of 
broad-spectrum anti-viral tripeptidyl inhibitors as depicted in Figure 1. 
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Figure 1. Synthesized and bioevaluated viral cysteine protease inhibitors 1 - 8.
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Our antiviral design focused on transition state inhibitors of 3Cpro and 3CLpro by 
incorporating a recognition element such as a peptidyl fragment that is compatible with the 
known substrate specificity of the targeted enzymes and a warhead such as an aldehyde, -
ketoamide, bisulfite adduct,13,14 or an -hydroxy phosphonate transition state mimic. Since the 
primary substrate specificity residue of 3Cpro and 3CLpro is a glutamine residue, a glutamine 
surrogate15,16 was therefore utilized in the P1 site of the inhibitors.  Like others,17,18 we found that 
a hydrophobic amino acid such as leucine residue at the P2 site enhances the recognition. 
Results of our cell-based assays have shown that a hydrophobic residue at P3 in the tripeptidyl 
compounds is important for manifesting antiviral activity, and those with arylalanine at P3 are 
highly active in cell-based assays as well as enzyme assays, suggesting that arylalanine at P3 is 
 4
important for cell penetration. Hence, a series of tripeptidyl molecules containing an aldehyde 
warhead of glutamine surrogate at P1, leucine at P2, and arylalanine at P3, such as 1 – 5, was 
first synthesized and evaluated. 
Tripeptidyl aldehydes 1 – 5 were readily synthesized using a five-step reaction sequence 
starting from glutamine surrogate methyl ester 1015 (Scheme 1). Hence, condensation of 10 and 
(S)-N-Boc-leucine (9) in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI) afforded dipeptide 11, which upon removal of the Boc group and coupling with various 
N-Cbz-amino acids 12a – 12e gave tripeptides 13 – 17, respectively in good yields. Reduction of 
the methyl ester function with sodium borohydride followed by oxidation with Dess-Martin 
periodinane (DMP) furnished aldehydes 1 – 5. Compounds 12a – 12d are commercially 
available, while 12e was made by following a reported procedure19 via a Suzuki coupling of (S)-
N-Boc-4-bromophenylalanine and phenylboronic acid followed by removal of the Boc group and 
installation of the Cbz group with benzyl chloroformate. 
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Scheme 1. Synthesis of viral cysteine protease inhibitors 1 - 5.
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To avoid oxidative degradation and improve absorption and in vivo pharmacokinetics, various 
warheads were installed13,14 by modifying the aldehyde function of compound 2.20 -Ketoamide 
6 was synthesized from a nucleophilic addition reaction of aldehyde 2 and isopropylisonitrile 
followed by hydration and oxidation with DMP.13 Bisulfite adduct 7 and -hydroxy phosphonate 
8 were readily prepared as pairs of alcohol diastereomers at the carbon adjacent to S or P from 
the addition of sodium sulfite14 and diethylphosphite,21 respectively, in ~1.3:1 ratio in both 
compounds based on 13C NMR spectral data. 
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Scheme 2. Synthesis viral cysteine protease inhibitors 6 - 8.
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The inhibitory activities of compounds 1 – 8 against NV were studied using a FRET-based 
enzyme22 and cell-based assays using the NV replicon cell system,23 and results are summarized 
in Table 1. The half maximum inhibitory concentration (IC50) or half maximum effective 
concentration (EC50) values of these compounds, except for compound 6, were found to be in the 
submicromolar ranges. Among different P3 residues, i.e., compounds 1 – 5, compound 2 
displayed the highest inhibitory activities both in the enzyme and cell-based assays. The D-
amino acid analog 3 exhibits lower activities than that of 2, and 2-naphthyl 4 and biphenyl 5 
showed slightly weaker activity than that of 2. Among different warheads, compounds 2 and 7 
possess the strongest activities. Bisulfite adduct 7 is a precursor and pro-drug of 2 through 
equilibrium in aqueous solution.14 It is possible that the activity of -hydroxy phosphonate 
(warhead) varies in different conditions in enzyme and cell-based assays. Nevertheless, 
compound 8 showed strong activity in NV replicon cells. 
Table 1 
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IC50 and EC50 values of Compounds 1 – 8 from NV 3CLpro FRET-based assay and NV replicon 
cells, respectively.24 
Compound IC50 (M) EC50 (M) 
  
  
  
  
  
  
  
  
 
We further examined the broad-spectrum inhibitory activities of compounds 2 and 6 against 
3Cpro or 3CLpro from NV, MD145, HRV, and SARS-CoV in the FRET-based enzyme assays 
(Table 2), and against NV, MNV-1, HRV18, and coronavirus 229E in cell culture systems (Table 
3). Both compounds effectively inhibited tested proteases and viruses. Moreover, tripeptidyl 2 
showed nanomolar inhibitory activity against all viruses, suggesting that a broad-spectrum 
inhibitor against multiple viruses can be achieved based on the conservation of the substrate 
binding pocket of 3Cpro and 3CLpro. 
Table 2   
IC50 values of two active tripeptidyl compounds, 2 and 6 against various 3Cpro and 3CLpro 
using FRET-based enzyme assays.24 
Compound NV (M) MD (M) HRV (M) SARS-CoV (M) 
    
    
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Table 3 
EC50 values of two active tripeptidyl compounds, 2 and 6, against various viruses in the cell-
based assays and CC50 (concentration that causes 50% cell death) values.24 
Compound NV (M) MNV- (M) HRV (M) Corona-virus 
E (M) 
CC (M) 
     
     
 
 
The enzyme selectivity of a representative inhibitor, compound 2, was assessed using a panel 
of proteases, including human neutrophil elastase, -chymotrypsin, trypsin, and thrombin. 
Inhibitor 2, up to 10 M, was found to display minimal or no activity against these enzymes. 
Highly potent inhibitors against noroviruses, picornaviruses and coronaviruses were 
discovered through the design of tripeptidyl transition state inhibitors and transition state mimics 
capable of binding to the active site of viral 3Cpro or 3CLpro.  The cell-based results suggest 
that a naphthylalanine residue at P3 site is important for antiviral activity of the tripeptidyl 
compounds. These inhibitors could be further developed as broad-spectrum antivirals against 
these important viruses. 
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